Paragon Partners is a private equity firm headquartered in Munich, Germany, that invests in medium-sized companies in the German-speaking region. The firm was founded in 2004 and has over €2.4 billion in assets under management. Paragon Partners’ investment strategy is…
KfW DEG (German Development Finance Corporation) is a subsidiary of the KfW Group and one of the world’s leading development finance institutions (DFIs). It is specialized in providing long-term capital,…
Deutsche Beteiligungs AG (DBAG) is a listed German investment company headquartered in Frankfurt am Main. It originates closed-end private equity funds and invests in well-positioned mid-market companies with potential. DBAG…
COI Partners is a private equity firm headquartered in Zurich, Switzerland, that invests in high-growth small and medium-sized companies in the German-speaking region. The firm was founded in 2001 and…
Dievini has a strong track record of success. Some of the company’s most notable investments include:
BioNTech (mRNA vaccines)
CureVac (mRNA vaccines)
Heidelberg Pharma (immunotherapies)
InflaRx (antibody therapies)
Morphosys (antibody therapies)
Translate Bio (mRNA therapeutics)
Dievini is an important investor in the German biotech sector and plays a key role in supporting the development of innovative new drugs and therapies. The company is committed to helping its portfolio companies achieve their full potential and bring their products to market.
Here are some of the key benefits of working with dievini:
Access to capital: dievini has a large pool of capital to invest in early-stage life science companies. The company offers a variety of financing solutions, including equity, mezzanine capital, and debt.
Expertise and resources: dievini has a team of experienced investment professionals with a deep understanding of the life science sector. The company is also able to provide its portfolio companies with a wide range of support services, including strategic advice, operational expertise, and access to a network of contacts.
Track record of success: dievini has a strong track record of success in investing in early-stage life science companies and helping them to achieve their full potential.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.